Sana (SANA) director awarded 90,000 stock options vesting in 2027

Rhea-AI Filing Summary

Sana Biotechnology director Robert Nelsen received a grant of stock options covering 90,000 shares of Common Stock. The options have an exercise price of $2.96 per share and expire on June 3, 2036. They vest 100% on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting, assuming continuous service. Following this grant, Nelsen holds options for 90,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider NELSEN ROBERT

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	90,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 90,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 90,000 options Exercise price: $2.96 per share Expiration date: June 3, 2036 +3 more

6 metrics

Options granted 90,000 options Stock Option (Right to Buy) granted to Robert Nelsen

Exercise price $2.96 per share Conversion or exercise price of granted options

Expiration date June 3, 2036 Option expiration for 90,000-share grant

Underlying shares 90,000 shares Underlying Sana common stock for the option grant

Post-grant option holdings 90,000 options Total options held following transaction

Vesting date trigger June 4, 2027 Earlier of this date or 2027 annual meeting, with continuous service

Key Terms

Stock Option (Right to Buy), grant/award acquisition, vests and becomes exercisable, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

vests and becomes exercisable financial

"The option vests and becomes exercisable as to 100% of the underlying shares"

annual meeting of stockholders financial

"immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NELSEN ROBERT

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 350

(Street)

SEATTLE WASHINGTON 98102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.96	06/04/2026		A		90,000		(1)	06/03/2036	Common Stock	90,000	$0	90,000	D

Explanation of Responses:

1. The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date

Remarks:

Exhibit List: Ex. 24 - Power of Attorney

	/s/ Aaron M. Grossman, Attorney-in-Fact for Robert Nelsen	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Robert Nelsen report in this Form 4 for Sana (SANA)?

Robert Nelsen reported receiving a grant of stock options for 90,000 Sana Biotechnology shares. These options are a compensation award, not an open-market stock purchase or sale, and give him the right to buy Sana common stock at a fixed exercise price.

What are the key terms of Robert Nelsen’s 90,000 Sana (SANA) stock options?

The options cover 90,000 shares of Sana common stock at an exercise price of $2.96 per share. They expire on June 3, 2036, giving Nelsen a long exercise window if vesting conditions and other requirements are satisfied.

When do Robert Nelsen’s Sana (SANA) stock options vest?

The options vest and become exercisable as to 100% of the 90,000 underlying shares on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting, provided he continues to serve the company until that date.

Is Robert Nelsen’s Form 4 transaction a market purchase or sale of Sana (SANA) shares?

No, this Form 4 shows a grant of stock options, not an open-market trade. The transaction is categorized as a grant or award acquisition, meaning it is part of his compensation rather than a discretionary buy or sell in the market.

How many Sana (SANA) options does Robert Nelsen hold after this grant?

After this reported transaction, Nelsen holds stock options for 90,000 shares of Sana common stock directly. This count reflects the options covered by the grant reported in the Form 4 and represents his position from this specific award.